Year All20242023202220212020201920182017201620152014 ABIVAX to Present at German Equity Forum 2017 November 22, 2017 Read More ABIVAX enrolls first ulcerative colitis patient in new ABX464 proof-of-concept clinical trial November 20, 2017 Read More ABIVAX to Present at BIO-Europe® 2017 – 23rd Annual International Partnering Conference October 30, 2017 Read More ABIVAX presents novel data on the efficacy of its immune enhancer ABX196 in animal model of liver cancer at the World Vaccine Congress October 12, 2017 Read More ABIVAX expands Scientific Advisory Board with appointment of renowned virologist and former President of the Pasteur Institute, Prof. Christian Bréchot October 05, 2017 Read More ABIVAX’s ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial September 28, 2017 Read More ABIVAX secures an equity line financing with Kepler Cheuvreux September 28, 2017 Read More ABIVAX receives French regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis September 20, 2017 Read More ABIVAX First-Half 2017 Financial Results and Update September 20, 2017 Read More FIRST PATIENT DOSED IN THREE-MONTH COHORT OF PHASE 2A STUDY OF ORAL ABX464 IN HIV-SUPPRESSED PATIENTS September 18, 2017 Read More
ABIVAX enrolls first ulcerative colitis patient in new ABX464 proof-of-concept clinical trial November 20, 2017 Read More
ABIVAX to Present at BIO-Europe® 2017 – 23rd Annual International Partnering Conference October 30, 2017 Read More
ABIVAX presents novel data on the efficacy of its immune enhancer ABX196 in animal model of liver cancer at the World Vaccine Congress October 12, 2017 Read More
ABIVAX expands Scientific Advisory Board with appointment of renowned virologist and former President of the Pasteur Institute, Prof. Christian Bréchot October 05, 2017 Read More
ABIVAX’s ABX464 Reduces HIV Reservoir in Blood in Second Phase 2a Clinical Trial September 28, 2017 Read More
ABIVAX receives French regulatory Approval to Begin Clinical Trial of ABX464 in Ulcerative Colitis September 20, 2017 Read More
FIRST PATIENT DOSED IN THREE-MONTH COHORT OF PHASE 2A STUDY OF ORAL ABX464 IN HIV-SUPPRESSED PATIENTS September 18, 2017 Read More
